© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
60% of women treated with the antibody-drug conjugate experienced complete or partial tumor shrinkage.
New targeted therapy improves survival in people with metastatic HER2-positive breast cancer.
The novel immune-enhancing antibody delays disease progression, especially in people with a common genetic variant.
Antibody-drug combination reduced the risk of recurrence after surgery by half compared with Herceptin.
Kadcyla reduces the risk of breast cancer recurring and spreading after surgery.
Experts say Kadcyla should become a new standard of care for adjuvant therapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
